Literature DB >> 15482172

Can virulence factors be viable antibacterial targets?

Andrea Marra1.   

Abstract

There is a real crisis in healthcare with the emergence of bacterial pathogens resistant to multiple drugs. The drug discovery industry is faced with the challenge of developing new classes of antibiotics that are effective against resistant organisms. Targeting bacterial virulence is one approach that has yet to be fully exploited, and the last decade or so has seen the development of reagents, screens and approaches that could make this possible. Several processes utilized by bacteria to cause infection are employed in a wide range of pathogens and as such may make attractive targets. Inhibitors of such targets would be unlikely to affect host cells, be cross-resistant to existing therapies and induce resistance themselves.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15482172     DOI: 10.1586/14787210.2.1.61

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  12 in total

Review 1.  The biology and future prospects of antivirulence therapies.

Authors:  Lynette Cegelski; Garland R Marshall; Gary R Eldridge; Scott J Hultgren
Journal:  Nat Rev Microbiol       Date:  2008-01       Impact factor: 60.633

2.  High-throughput assessment of bacterial growth inhibition by optical density measurements.

Authors:  Jennifer Campbell
Journal:  Curr Protoc Chem Biol       Date:  2011-10-01

3.  Mycobacterial phenolic glycolipid virulence factor biosynthesis: mechanism and small-molecule inhibition of polyketide chain initiation.

Authors:  Julian A Ferreras; Karen L Stirrett; Xuequan Lu; Jae-Sang Ryu; Clifford E Soll; Derek S Tan; Luis E N Quadri
Journal:  Chem Biol       Date:  2007-12-27

Review 4.  Toxin-antitoxin genes of the Gram-positive pathogen Streptococcus pneumoniae: so few and yet so many.

Authors:  Wai Ting Chan; Inma Moreno-Córdoba; Chew Chieng Yeo; Manuel Espinosa
Journal:  Microbiol Mol Biol Rev       Date:  2012-12       Impact factor: 11.056

Review 5.  Protein Disulfide Exchange by the Intramembrane Enzymes DsbB, DsbD, and CcdA.

Authors:  John H Bushweller
Journal:  J Mol Biol       Date:  2020-04-16       Impact factor: 5.469

6.  Syntheses and biological evaluation of 2-amino-3-acyl-tetrahydrobenzothiophene derivatives; antibacterial agents with antivirulence activity.

Authors:  Hung The Dang; Erik Chorell; Hanna Uvell; Jerome S Pinkner; Scott J Hultgren; Fredrik Almqvist
Journal:  Org Biomol Chem       Date:  2014-02-17       Impact factor: 3.876

Review 7.  One cannot rule them all: Are bacterial toxins-antitoxins druggable?

Authors:  Wai Ting Chan; Dolors Balsa; Manuel Espinosa
Journal:  FEMS Microbiol Rev       Date:  2015-03-21       Impact factor: 16.408

Review 8.  Bygiene: The New Paradigm of Bidirectional Hygiene.

Authors:  Gabriel A Al-Ghalith; Dan Knights
Journal:  Yale J Biol Med       Date:  2015-11-24

9.  A Systematic Overview of Type II and III Toxin-Antitoxin Systems with a Focus on Druggability.

Authors:  Sung-Min Kang; Do-Hee Kim; Chenglong Jin; Bong-Jin Lee
Journal:  Toxins (Basel)       Date:  2018-12-04       Impact factor: 4.546

Review 10.  The antigenome: from protein subunit vaccines to antibody treatments of bacterial infections?

Authors:  Carmen Giefing; Eszter Nagy; Alexander von Gabain
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.